Nimodipine in Clinical Practice: A Pharmacological Update

Brendon Clough, Josephine Tenii, Claribel Wee, Elizabeth Gunter, Tara Griffin, Venkatesh Aiyagari

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


INTRODUCTION: Enteral nimodipine provides a neuroprotective effect in patients who have experienced an aneurysmal subarachnoid hemorrhage (aSAH). Nimodipine remains the only US Food and Drug Administration-approved medication for aSAH.CONTENT: Nimodipine has been prescribed for patients with aSAH; however, little is known about factors to consider regarding dosing or patient-specific variables that may affect tolerability to nimodipine. Clinical impact of dose or dosing frequency changes has also been much debated based on risk of hypotension with currently approved dosing regimens. CONCLUSION: This review article addresses factors to consider for dosing and administration, pharmacokinetic and pharmacogenetic impact on nimodipine, and, finally, drug interaction considerations to assess as patients are initiated on enteral nimodipine for aSAH.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalJournal of Neuroscience Nursing
Issue number1
StatePublished - Feb 1 2022
Externally publishedYes


  • Aneurysm
  • Cerebral artery vasospasm
  • Nimodipine
  • Nimotop
  • Nursing
  • Nymalize
  • Pharmacology
  • Stroke
  • Subarachnoid hemorrhage

ASJC Scopus subject areas

  • Surgery
  • Endocrine and Autonomic Systems
  • Clinical Neurology
  • Medical–Surgical


Dive into the research topics of 'Nimodipine in Clinical Practice: A Pharmacological Update'. Together they form a unique fingerprint.

Cite this